S-4566-119
Read twice and referred to the Committee on Finance. (text: CR S2377-2379)
Sponsored by Richard Durbin (D-IL)
What it does
This bill would require all state Medicaid programs to cover annual lung cancer screenings at no cost to patients who meet U.S. Preventive Services Task Force (USPSTF) eligibility guidelines, and would ban prior authorization requirements for those screenings. It would also expand existing Medicaid tobacco cessation benefits — currently limited to pregnant women — to all Medicaid enrollees, and would extend the prior authorization ban for lung cancer screenings to Medicare and private insurance plans. Additionally, the bill would authorize $10 million per year from 2028 through 2032 for a public education and outreach campaign, and would direct the Comptroller General to study gaps in current screening eligibility guidelines.
Who benefits
Current and former heavy smokers aged 50–80 who are Medicaid enrollees and meet USPSTF screening criteria. All Medicaid enrollees who use tobacco products (including e-cigarettes and vape pens), who would gain access to cessation counseling and pharmacotherapy without prior authorization. Medicare beneficiaries and privately insured individuals who would no longer face prior authorization delays for lung cancer screenings. Lung cancer advocacy organizations involved in the outreach campaign. Potentially underscreened populations — such as firefighters, veterans, and women under 50 — who may benefit from the GAO study's recommendations. Providers who would face fewer administrative barriers to ordering screenings.
Who is hurt
State Medicaid programs and their budgets, which would bear a share of the new mandatory coverage costs. Medicaid managed care organizations, which would lose the ability to use prior authorization as a cost-control tool for these services. Private insurers and Medicare Advantage plans, which would similarly lose prior authorization flexibility. Taxpayers broadly, who would fund the federal share of expanded Medicaid benefits and the $50 million outreach appropriation. States that currently do not cover these services and would need to pass conforming legislation, facing administrative transition costs. Tobacco cessation drug manufacturers that currently benefit from the more limited coverage pool may face increased pricing scrutiny as the covered population expands.
Supporters argue
Supporters argue that lung cancer is the leading cause of cancer death in the United States, killing more than 125,000 Americans annually, yet low-dose CT screening — which the USPSTF recommends for high-risk individuals — remains significantly underutilized, with studies showing fewer than 6% of eligible patients receiving it. They contend that cost-sharing requirements and prior authorization delays are documented barriers to screening access, particularly for low-income Medicaid enrollees, and that early detection dramatically improves survival rates. Expanding tobacco cessation coverage to all Medicaid enrollees, they argue, addresses the root cause of the majority of lung cancer cases and reduces long-term program costs.
Opponents argue
Opponents argue that mandating coverage without prior authorization removes a key tool states and insurers use to ensure screenings are clinically appropriate and to manage costs, potentially leading to overutilization among individuals who do not meet evidence-based criteria. They contend that expanding Medicaid mandates imposes new unfunded obligations on states, which already face fiscal pressure, and that the Spending Clause coercion doctrine — recognized in NFIB v. Sebelius (2012) — raises questions about whether states retain genuine choice when federal conditions are attached to Medicaid funding. Critics may also argue that the $50 million outreach appropriation duplicates existing public health infrastructure without demonstrated cost-effectiveness.